Comparisons

Mounjaro vs Zepbound: Same Drug, Different Indication

Thu May 07 2026

At a Glance

Same tirzepatide. Different FDA label. Same outcomes.

Mounjaro and Zepbound are identical tirzepatide pens manufactured by Eli Lilly. The only difference is the FDA indication: Mounjaro is approved for type 2 diabetes (SURPASS program — 11.2 kg weight loss at 15 mg over 40 weeks), Zepbound for chronic weight management (SURMOUNT-1 — 22.5% body-weight loss at 15 mg over 72 weeks). Same molecule, same dose strengths (2.5 → 15 mg), same titration schedule, same side-effect profile.

This article is most relevant for the patient whose insurance covers Mounjaro for diabetes but denies Zepbound for weight loss — or vice versa — and who needs to understand why a prescriber might choose one label over the other when the contents are pharmacologically interchangeable.

2026 cash-pay pricing reveals the absurdity: Mounjaro retails at ~$1,069/month, Zepbound at ~$1,086/month — same drug, $17/month difference. Zepbound vials through LillyDirect drop to $349–$499/month. Compounded tirzepatide through Ozari is $125/month on the 3-month starter plan, ~$199/month ongoing — the identical molecule at roughly 1/5 the brand price, prescribed and shipped by licensed US pharmacies.

Mounjaro vs Zepbound: Same Drug, Different Indication

If you've been researching weight loss medications or diabetes treatments, you may have come across both Mounjaro and Zepbound. Here's something that confuses many people: these are actually the exact same medication with the same active ingredient, but they're approved for different uses.

Both contain tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. The distinction between Mounjaro and Zepbound isn't about what's in the injection—it's about what the FDA has officially approved each one to treat.

Let's break down what makes these two brands different, and what that means for you.

What Is Tirzepatide?

Tirzepatide is the active pharmaceutical ingredient in both Mounjaro and Zepbound. It works by mimicking two natural hormones in your body: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

These hormones help regulate blood sugar levels, slow digestion, reduce appetite, and influence how your body stores fat. By activating both pathways simultaneously, tirzepatide offers a unique mechanism of action that's shown impressive results in clinical trials.

The medication is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm.

Mounjaro: FDA-Approved for Type 2 Diabetes

Mounjaro received FDA approval in May 2022 as a treatment for type 2 diabetes. It's prescribed to improve blood sugar control in adults with this condition, typically alongside diet and exercise.

In clinical trials, Mounjaro demonstrated significant reductions in A1C levels (a measure of average blood sugar over time). Many patients also experienced substantial weight loss as a secondary benefit, which caught the attention of both healthcare providers and the public.

However, Mounjaro's official FDA indication is specifically for diabetes management. That said, doctors can prescribe it off-label for weight loss if they determine it's appropriate for a patient.

Zepbound: FDA-Approved for Weight Management

Zepbound received FDA approval in November 2023, making it the first and only tirzepatide product officially approved for chronic weight management.

It's indicated for adults with obesity (BMI of 30 or greater) or those who are overweight (BMI of 27 or greater) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The approval was based on the SURMOUNT clinical trial program, which showed that participants lost an average of 15-20% of their body weight when using tirzepatide alongside lifestyle modifications.

Zepbound is prescribed specifically for weight loss, making it the appropriate choice when weight management—not diabetes—is the primary treatment goal.

The Key Difference: FDA Indication

The most important distinction between Mounjaro and Zepbound is their FDA-approved indication—the specific condition each is officially approved to treat.

Think of it like this: the medication inside is identical, but the label on the box tells healthcare providers and insurance companies what condition it's meant for. This difference affects how doctors prescribe these medications and how insurance companies cover them.

Mounjaro is indicated for type 2 diabetes. Zepbound is indicated for chronic weight management. Same drug, different purpose on paper.

Insurance Coverage Considerations

The different indications can significantly impact insurance coverage. Many insurance plans cover diabetes medications more readily than weight loss treatments, since diabetes is viewed as a medical condition requiring treatment.

Weight loss medications historically face more coverage restrictions, with some plans excluding them entirely. This means Mounjaro might be covered for a patient with type 2 diabetes, while Zepbound might not be covered for the same patient seeking weight loss—even though they contain the identical medication.

If insurance coverage is a barrier, compounded versions of tirzepatide may offer a more affordable alternative. These are custom-prepared formulations available through specialized pharmacies at a significantly lower cost.

You can read more about compounded options on ozarihealth.com/blog.

Which One Should You Take?

The choice between Mounjaro and Zepbound should be based on your primary treatment goal and your healthcare provider's recommendation.

If you have type 2 diabetes and need better blood sugar control, Mounjaro is the appropriate choice. If your primary goal is weight loss and you meet the criteria for chronic weight management treatment, Zepbound is specifically approved for that purpose.

That said, the clinical reality is more nuanced. Because both contain tirzepatide, they work the same way in your body. Your doctor may prescribe based on factors like insurance coverage, availability, and what will be most cost-effective for you.

Key Takeaways

Mounjaro and Zepbound contain the exact same active ingredient—tirzepatide—at the same doses, administered the same way
Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved specifically for chronic weight management
The main difference is the indication, which affects how doctors prescribe them and how insurance companies cover them
Compounded tirzepatide offers an affordable alternative to both brand-name medications, often at a fraction of the cost

Frequently Asked Questions

Is Mounjaro or Zepbound more effective for weight loss?

Since both contain the same active ingredient (tirzepatide) at the same doses, they are equally effective for weight loss. The difference is only in their FDA-approved indication. Clinical trials have shown tirzepatide produces significant weight loss regardless of which brand name is on the label.

Can I get Mounjaro prescribed for weight loss if I don't have diabetes?

Yes, doctors can prescribe Mounjaro off-label for weight loss, meaning they prescribe it for a purpose other than its FDA-approved indication. However, insurance coverage may be limited for off-label use, and Zepbound might be the more appropriate choice if weight management is your primary goal.

Are there differences in side effects between Mounjaro and Zepbound?

No. Since they contain the identical medication, the side effect profile is the same. Common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation. These typically improve as your body adjusts to the medication.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.

Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.